Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

GMAB Genmab A/S

休市中 10-23 16:00:00 EDT

43.79

+3.79

+9.48%

盘后43.85

+0.06+0.14%

19:57 EDT

最高44.34	最低39.64	成交量1,300万
今开39.84	昨收40.00	日振幅11.76%
总市值269.31亿	流通市值252.23亿	总股本6.15亿
成交额5.55亿	换手率2.26%	流通股本5.76亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"GMAB","market":"US","secType":"STK","nameCN":"Genmab A/S","latestPrice":43.79,"timestamp":1792785600000,"preClose":40,"halted":0,"volume":13000820,"hourTrading":{"tag":"盘后","latestPrice":43.85,"preClose":43.79,"latestTime":"19:57 EDT","volume":545537,"amount":23891818.5169,"timestamp":1792799846350,"change":0.06,"changeRate":0.00137,"amplitude":0.006017},"delay":0,"changeRate":0.09474999999999997,"floatShares":576000000,"shares":615000000,"eps":1.26503,"marketStatus":"休市中","change":3.79,"latestTime":"10-23 16:00:00 EDT","open":39.84,"high":44.34,"low":39.635,"amount":554665463.38406,"amplitude":0.117625,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.26503,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793001600000},"marketStatusCode":7,"adr":0,"adrRate":0.1,"listingDate":1563422400000,"exchange":"NASDAQ","adjPreClose":40,"preHourTrading":{"tag":"盘前","latestPrice":39.84,"preClose":40,"latestTime":"09:29 EDT","volume":4832,"amount":191688.36336000002,"timestamp":1792762199999,"change":-0.16,"changeRate":-0.004,"amplitude":0.01375},"postHourTrading":{"tag":"盘后","latestPrice":43.85,"preClose":43.79,"latestTime":"19:57 EDT","volume":545537,"amount":23891818.5169,"timestamp":1792799846350,"change":0.06,"changeRate":0.00137,"amplitude":0.006017},"volumeRatio":3.439399,"optionData":{"bulkOrders":[{"symbol":"GMAB","call":false,"expireDate":1799989200000,"strike":"35.0","timestamp":1792774075930,"price":1.45,"volume":2000,"amount":290000,"type":"-"},{"symbol":"GMAB","call":false,"expireDate":1799989200000,"strike":"30.0","timestamp":1792774075930,"price":0.5,"volume":2000,"amount":100000,"type":"-"}]},"impliedVol":0.6541,"impliedVolPercentile":0.7968},"requestUrl":"/m/hq/s/GMAB","defaultTab":"news","newsList":[{"id":"2677276908","title":"CLDN18.2靶向ADC 3期研究达到双主要终点；双靶点ADC 3期结果积极……","url":"https://stock-news.laohu8.com/highlight/detail?id=2677276908","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677276908?lang=zh_cn&edition=full","pubTime":"2026-10-24 07:35","pubTimestamp":1792798500,"startTime":"0","endTime":"0","summary":" CLDN18.2靶向ADC国际3期研究达到双主要终点，延长胃癌患者PFS和OS 武田(Takeda)和信达生物(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tava ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261024/c681047440.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261024/c681047440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["FFBC","LU1430594728.SGD","BK4195","LU0432979614.USD","IE00BFTCPJ56.SGD","LU1291159041.SGD","LU1670711123.USD","LU1032466523.USD","LU1670710661.SGD","IHE","LU1074936037.SGD","ORR","PFS","LU2596442595.SGD","LU0985481810.HKD","LU0456855351.SGD","LU0237698245.USD","BK4211","IE00BFXG1179.USD","LU2125154935.USD","NETL","LU0096364046.USD","LU1670711040.USD","LU1261432733.SGD","BK4532","BK4559","ADC","LU1236620750.USD","BK4581","LU2360032135.SGD","LU0225284248.USD","BK4231","BK4585","LU2242646821.SGD","LU0306806265.USD","IE0009355771.USD","LU0114720955.EUR","LU2133065610.SGD","IE00BSNM7G36.USD","BK4534","FTXH","ITT","LU0321505868.SGD","LU1983299246.USD","BK4139","LU0061475181.USD","LU1571399168.USD","GMAB","LU1868837136.USD","BMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170095179","title":"异动解读｜Genmab A/S盘中上涨6.9%，卵巢癌三期试验达到主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1170095179","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170095179?lang=zh_cn&edition=full","pubTime":"2026-10-24 01:22","pubTimestamp":1792776145,"startTime":"0","endTime":"0","summary":"10月24日，Genmab A/S盘中上涨6.9%，报42.76美元，成交额2.98亿美元。消息面上，公司披露候选药物Rina-S在铂耐药性卵巢癌三期试验中达到无进展生存期主要终点，并达到总生存期关键次要终点，推动股价走强。数据显示，Rina-S较研究者选择化疗使总体人群疾病进展或死亡风险降低71%，主要分析集降低67%；同时使死亡风险降低57%。公司称安全性与既往结果一致，未发现新的安全问题，并计划与全球监管机构沟通后续申报事宜。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Genmab卵巢癌三期达标，股价强势上涨","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131752637","title":"异动解读｜Genmab A/S盘中上涨11.11%，Rina-S卵巢癌试验缓解率达45.9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131752637","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1131752637?lang=zh_cn&edition=full","pubTime":"2026-10-06 03:03","pubTimestamp":1791227000,"startTime":"0","endTime":"0","summary":"10月6日，Genmab A/S盘中上涨11.11%，报38.62美元/股。消息面源于该公司公告其在铂耐药卵巢癌1/2期试验中达到45.9%确认缓解率，其中5名患者无检出癌征且中位无进展生存期9.5个月。Genmab A/S为国际生物技术公司，专注于开发基于抗体的癌症等重病疗法，目前已在新增3期试验中推进该药物。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Genmab异动拉升，卵巢癌新药缓解率亮眼","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157485485","title":"财报前瞻｜Genmab A/S本季度营收预计增24.09%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1157485485","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157485485?lang=zh_cn&edition=full","pubTime":"2026-07-30 10:36","pubTimestamp":1785379014,"startTime":"0","endTime":"0","summary":"Genmab A/S将于2026年08月06日发布最新财报，市场预期营收、EBIT维持同比增长，EPS或受研发与合作费用节奏影响承压。市场一致预期本季度Genmab A/S营收为11.12亿美元，同比增长24.09%；EBIT为3.50亿美元，同比增长10.42%；调整后每股收益为0.35美元，同比下降21.09%。上季度Genmab A/S营收为8.96亿美元，同比增长25.32%；毛利率为92.75%；归属于母公司股东的净利润为5,300.00万美元，净利率为5.92%；调整后每股收益为0.08美元，同比下降72.79%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Genmab A/S本季度营收预计增24.09%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153094826","title":"财报前瞻｜Genmab A/S本季度营收预计增17.37%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1153094826","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1153094826?lang=zh_cn&edition=full","pubTime":"2026-04-30 17:02","pubTimestamp":1777539761,"startTime":"0","endTime":"0","summary":"Genmab A/S将于2026年05月07日发布财报，围绕营收与利润预期的变化成为关注点。一致预期显示，本季度公司营收约8.88亿美元，同比+17.37%；调整后每股收益约0.18美元，同比-23.33%；公司未披露本季度毛利率、净利润或净利率的明确指引。结合一致预期对本季度营收同比+17.37%的判断，以及多家机构延续“买入”立场的情况，当前市场主流观点偏向乐观，更关注单季利润率的边际改善与全年收入指引的执行度。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Genmab A/S本季度营收预计增17.37%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518271854","title":"Genmab As盘中异动 急速下挫6.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271854","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518271854?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:13","pubTimestamp":1741616005,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时13分，Genmab As股票出现异动，股价大幅下挫6.75%。Genmab As股票所在的生物技术行业中，整体涨幅为0.21%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221325abf30c0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310221325abf30c0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171629140","title":"异动解读 | Genmab业绩超预期 股价盘中大涨6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=1171629140","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171629140?lang=zh_cn&edition=full","pubTime":"2025-02-14 01:02","pubTimestamp":1739466163,"startTime":"0","endTime":"0","summary":"生物技术公司Genmab A/S(GMAB)今日盘中大涨6.53%,引发市场广泛关注。\n\n消息面上,Genmab公布2024财年业绩,全年营收215.3亿丹麦克朗,超过分析师预期的213.9亿克朗,这一良好业绩成为GMAB股价大涨的主因。\n\n公司简介显示,Genmab是一家总部位于丹麦哥本哈根的生物技术公司,专注于研发用于治疗癌症的抗体疗法。其主要产品包括治疗多发性骨髓瘤的Darzalex、治疗甲状腺眼病的Tepezza等。公司目前还拥有多个治疗其他肿瘤的候选药物在研。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | Genmab业绩超预期 股价盘中大涨6.53%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511655520","title":"【明晟公司MSCI北欧国家指数涨0.6%，报379.67点】明晟公司MSCI北欧国家指数涨0.6%，报379.67点。开发癌症抗体疗法的生物技术公司Genmab A/S涨8.5%，领跑一众成分股。最新业绩报告显示，该公司全年营收215.3亿丹麦克朗，分析师预期213.9亿克朗。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511655520","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511655520?lang=zh_cn&edition=full","pubTime":"2025-02-14 00:52","pubTimestamp":1739465543,"startTime":"0","endTime":"0","summary":"明晟公司MSCI北欧国家指数涨0.6%，报379.67点。开发癌症抗体疗法的生物技术公司Genmab A/S涨8.5%，领跑一众成分股。最新业绩报告显示，该公司全年营收215.3亿丹麦克朗，分析师预期213.9亿克朗。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/14005248150518.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["MSCI","GNMSF","GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2511010521","title":"Genmab As盘中异动 早盘股价大涨5.03%报20.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511010521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2511010521?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:29","pubTimestamp":1739460567,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时29分，Genmab As股票出现异动，股价快速拉升5.03%。截至发稿，该股报20.68美元/股，成交量68.9807万股，换手率0.11%，振幅3.25%。Genmab As股票所在的生物技术行业中，整体涨幅为0.13%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232927a244b7ef&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213232927a244b7ef&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2506148755","title":"Genmab As盘中异动 早盘股价大跌7.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2506148755","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2506148755?lang=zh_cn&edition=full","pubTime":"2025-01-28 22:31","pubTimestamp":1738074664,"startTime":"0","endTime":"0","summary":"北京时间2025年01月28日22时31分，Genmab As股票出现异动，股价急速下跌7.88%。Genmab As股票所在的生物技术行业中，整体涨幅为0.01%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128223104abbb656c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250128223104abbb656c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2505478293","title":"Genmab As盘中异动 快速拉升5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505478293","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2505478293?lang=zh_cn&edition=full","pubTime":"2025-01-22 04:49","pubTimestamp":1737492596,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日04时49分，Genmab As股票出现异动，股价急速上涨5.00%。Genmab As股票所在的生物技术行业中，整体涨幅为1.76%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122044956986e737b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122044956986e737b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2504449484","title":"特朗普2.0时代即将开启，投资机会如何掘金？","url":"https://stock-news.laohu8.com/highlight/detail?id=2504449484","media":"招商基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504449484?lang=zh_cn&edition=full","pubTime":"2025-01-20 10:36","pubTimestamp":1737340585,"startTime":"0","endTime":"0","summary":"美国候任总统唐纳德·特朗普将于美东时间1月20日12时正式宣誓就任美国第47任总统。特朗普2.0时代即将开启，有哪些投资机会可以布局？值得一提的是，科技股在特朗普任期内表现尤为突出，成为推动美股上涨的主要力量。在特朗普第一个任期内，美元整体表现相对弱势。4年任期内，美元指数累计下跌了10.53%。而纵观全球市场，在特朗普上一任期内，恒生科技指数涨幅超过147%，表现甚至略微优于纳斯达克指数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250120103318abb12e8e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["WBA","CPRT","HOOD","HTHT","QCOM","CHKP","MARA","ENPH","MTCH","LOGI","PAA","GNTX","AVGO","LU2065731478.USD","DOX","AZN","FAST","MPWR","COKE","DOCU","BK4561","ILMN","PCAR","CRWD","CSX","CSGP","CASY","TCOM","ON","TSEM","ZS","NTAP","DUOL","BSY","TROW","RKLB","CTSH","FYBR","MNDY","ADSK",".IXIC","AAPL","NTRA","AEP","COIN","MELI","ROST","CYBR","LKQ","INCY","RGLD","TQQQ","LI","GLPI","NTNX","RYAAY","BK4588","GILD","MANH","LULU","BK4581","BKR","FRPT","MDLZ","ODFL","OTEX","MNQmain","FSV","SBUX","REGN","NQmain","ADBE","ALGN","LPLA","RVMD","TTEK","PDD","COST","CSWI","CSCO","TSYW.SI","MCHP","EVRG","ORLY","APA","MDB","MEDP","SWKS","EXE","DDOG","SSNC","HOLX","FSLR","EWBC","NVDA","ALAB","NTES","DLTR","BRKR","BK4585","HST","EXAS","NWSA","RPRX","HBAN","ULTA","CME","WDC","BKNG","CHTR","PCTY","TW","ITCI","FTNT","ERIC","TRMB","SBAC","INTC","FWONK","GRAB","Z","CHRD","FOXA","JKHY","TMUS","BK4086","BPOP","CDNS","SMCI","STLD","ISRG","NICE","PTC","TER","ASML","AMAT","BK4550","SFM","NBIX","QXO","ESLT","LU0053671581.USD","LSTR","MRVL","SIRI","FTAI","ICLR","RADX","IDXX","ARGX","CPB","SQQQ","AAL","JBHT","OKTA","STX","META","LU0757428866.USD","CBSH","DPZ","FOX","AMGN","AAON","CCEP","ENTG","PFG","HSIC","PNFP","MIDD","LNW","PARA","PSQ","USAW.SI","SAIA","QRVO","QQQ","FFIV","SOFI","HON","ROP","NVIW.SI","BIIB","PEP","LAMR","TTD","TXN","CWST","GTLB","CFLT","LNT","RGEN","SRPT","KHC","ARM","MKSI","FER","ROKU","CHRW","AUR","GMAB","HLNE","PAYX","JD","AXON","MTSI","LSCC","HQY","CDW","MKTX","COO","LECO","WWD","WYNN","MRNA","TSLA","NDSN","ALNY","AMZN","BK4534","MMYT","NTRS","NXPI","POOL","TPG","TEAM","LIN","PCVX","DASH","EBAY","INTU","MSFT","ONC","TLN","DKNG","INSM","PLTR","SEIC","CZR","ROIV","CHDN","EQIX","AGNC","BMRN","ANSS","ERIE","KDP","AMD","PODD","AKAM","EXPE","FCNCA","BPMC","NFLX","SNPS","RIVN","USJW.SI","CINF","AFRM","GEHC","DSGX","MNST","NDAQ","BK4593","TSCO","GEN","EA","TTWO","NVMI","ADI","LU1815336091.USD","CTAS","QID","QLD","OLED","GOOGL","WTFC","ZM","CG","TECH","CEG","REG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2504324917","title":"Genmab As盘中异动 快速拉升5.02%报21.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2504324917","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2504324917?lang=zh_cn&edition=full","pubTime":"2025-01-17 00:33","pubTimestamp":1737045229,"startTime":"0","endTime":"0","summary":"北京时间2025年01月17日00时33分，Genmab As股票出现异动，股价急速上涨5.02%。截至发稿，该股报21.25美元/股，成交量72.363万股，换手率0.11%，振幅2.67%。Genmab As股票所在的生物技术行业中，整体跌幅为0.39%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117003349a2247bf5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250117003349a2247bf5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503640827","title":"Genmab As盘中异动 早盘股价大跌5.82%报20.38美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503640827","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2503640827?lang=zh_cn&edition=full","pubTime":"2025-01-15 22:31","pubTimestamp":1736951484,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日22时31分，Genmab As股票出现波动，股价大幅下挫5.82%。截至发稿，该股报20.38美元/股，成交量8.5026万股，换手率0.01%，振幅0.37%。Genmab As股票所在的生物技术行业中，整体涨幅为0.68%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223124a222fda1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250115223124a222fda1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483638585","title":"Genmab As2024财年第三财季实现净利润1.86亿美元，同比减少40.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483638585","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2483638585?lang=zh_cn&edition=full","pubTime":"2024-11-15 00:01","pubTimestamp":1731600070,"startTime":"0","endTime":"0","summary":"11月15日，Genmab As公布财报，公告显示公司2024财年第三财季净利润为1.86亿美元，同比减少40.19%；其中营业收入为8.16亿美元，同比增加17.92%，每股基本收益为0.29美元。从资产负债表来看，Genmab As总负债11.58亿美元，其中短期债务13.62百万美元，资产负债比为5.13，流动比率为5.18。机构评级：截至2024年11月15日，当前有20家机构对Genmab As目标价做出预测，其中目标均价为36.89美元，其中最低目标价为26.18美元，最高目标价为50.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000126a238003b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115000126a238003b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2469112856","title":"Genmab As盘中异动 股价大跌5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2469112856","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2469112856?lang=zh_cn&edition=full","pubTime":"2024-09-23 21:32","pubTimestamp":1727098320,"startTime":"0","endTime":"0","summary":"北京时间2024年09月23日21时32分，Genmab As股票出现波动，股价大幅下跌5.19%。Genmab As股票所在的生物技术行业中，整体跌幅为0.26%。Genmab As公司简介：Genmab AS是一家总部位于哥本哈根的生物技术公司，专门从事用于治疗癌症的抗体疗法。Genmab的专有抗体技术是DuoBody、HexaBody、DuoHexaBody和HexElect。强生公司与Genmab公司合作开发了Darzalex，该药物被视为多发性骨髓瘤的标准治疗药物，是Genmab公司的主要产品。Genmab公司还拥有多个针对其他肿瘤适应症的候选药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240923213200ab655c41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240923213200ab655c41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","GMAB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genmab.com","stockEarnings":[{"period":"1week","weight":0.1835},{"period":"1month","weight":0.2601},{"period":"3month","weight":0.5168},{"period":"6month","weight":0.6297},{"period":"1year","weight":0.466},{"period":"ytd","weight":0.4218}],"compareEarnings":[{"period":"1week","weight":-0.0043},{"period":"1month","weight":-0.0102},{"period":"3month","weight":0.0285},{"period":"6month","weight":0.0645},{"period":"1year","weight":0.1313},{"period":"ytd","weight":0.1145}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Genmab A/S于1998年6月11日注册成立。该公司是一家国际生物技术公司，拥有一系列基于抗体的新型产品和候选产品，旨在满足癌症和其他严重疾病患者的医疗需求，并改善其治疗结果。公司建立其产品线的目标是在他们认为能够最大化其价值并对治疗领域产生有意义影响的地理区域，将药物推向市场。","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.047195},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.023242},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.023166},{"month":4,"riseRate":0.571429,"avgChangeRate":0.046297},{"month":5,"riseRate":0.428571,"avgChangeRate":0.024549},{"month":6,"riseRate":0.571429,"avgChangeRate":0.011635},{"month":7,"riseRate":1,"avgChangeRate":0.074646},{"month":8,"riseRate":0.625,"avgChangeRate":0.058933},{"month":9,"riseRate":0.25,"avgChangeRate":-0.012715},{"month":10,"riseRate":0.5,"avgChangeRate":0.012375},{"month":11,"riseRate":0.714286,"avgChangeRate":0.070997},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.017923}],"exchange":"NASDAQ","name":"Genmab A/S","nameEN":"Genmab A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Genmab A/S(GMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Genmab A/S,GMAB,Genmab A/S股票,Genmab A/S股票老虎,Genmab A/S股票老虎国际,Genmab A/S行情,Genmab A/S股票行情,Genmab A/S股价,Genmab A/S股市,Genmab A/S股票价格,Genmab A/S股票交易,Genmab A/S股票购买,Genmab A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genmab A/S(GMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Genmab A/S(GMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}